Innehållet på denna webbplats är endast avsett för veterinärer eller andra professionella inom djurhälsovård.
Genom att använda denna webbplats accepterar du ovanstående.
Intervacc’s variation application approved by VMD
Intervacc AB (publ) today announces that the variation application previously submitted to the U.K’s Veterinary Medicines Directorate, (VMD), has now been approved. The approval concerns improved methods and processes which are a part of the manufacturing process for...Intervacc announces changes in the Nomination Committee
Stockholm, March 17, 2025 – The composition of the Nomination Committee in Intervacc AB (publ) (“Intervacc”) has changed due to the recently completed rights issue. The members of the Nomination Committee have been appointed in accordance with the principles for...Intervacc announces the outcome of the rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER...Intervacc’s variation application approved by European Medicines Agency
Stockholm, February 13, 2025 – Intervacc AB (publ) today announces that the variation application previously submitted to the European Medicines Agency (EMA) has now been approved. The approval concerns improved methods and processes which are a part of the...Intervacc AB (publ) publishes supplement to the prospectus regarding the rights issue
NOT FOR PUBLICATION, RELEASE OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER...Nyhetstjänster
